Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novartis AG (NVS)

82.19   -0.59 (-0.71%) 03-17 16:00
Open: 82.76 Pre. Close: 82.78
High: 83.08 Low: 81.86
Volume: 2,361,656 Market Cap: 174,211(M)

Technical analysis

as of: 2023-03-20 8:48:15 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 99.27     One year: 102.9
Support: Support1: 79.98    Support2: 66.54
Resistance: Resistance1: 84.99    Resistance2: 88.09
Pivot: 83.12
Moving Average: MA(5): 82.15     MA(20): 83.98
MA(100): 87.04     MA(250): 85.5
MACD: MACD(12,26): -1.6     Signal(9): -1.6
Stochastic oscillator: %K(14,3): 36.9     %D(3): 32.6
RSI: RSI(14): 38.4
52-week: High: 94.26  Low: 74.08
Average Vol(K): 3-Month: 2,031 (K)  10-Days: 2,238 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NVS ] has closed above bottom band by 35.4%. Bollinger Bands are 11.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 83.15 - 83.57 83.57 - 83.84
Low: 80.85 - 81.41 81.41 - 81.77
Close: 81.38 - 82.23 82.23 - 82.77

Company Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Headline News

Mon, 20 Mar 2023
Analysts have given Novartis AG (NYSE:NVS) an average ... - Best Stocks

Mon, 20 Mar 2023
Centaurus Financial Inc. Increases Stake in Novartis AG (NYSE:NVS) - Defense World

Mon, 20 Mar 2023
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained ... - Nasdaq

Sat, 18 Mar 2023
Single Point Partners LLC Purchases New Position in Novartis AG ... - MarketBeat

Fri, 17 Mar 2023
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain ... - Yahoo Finance

Thu, 16 Mar 2023
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 2,120 (M)
Shares Float 2,030 (M)
% Held by Insiders 0 (%)
% Held by Institutions 8.1 (%)
Shares Short 6,600 (K)
Shares Short P.Month 5,510 (K)

Stock Financials

EPS 3.17
EPS Est Next Qtl 1.27
EPS Est This Year 4.75
EPS Est Next Year 5.25
Book Value (p.s.) 28
Profit Margin (%) 13.4
Operating Margin (%) 24.8
Return on Assets (ttm) 6.4
Return on Equity (ttm) 10.9
Qtrly Rev. Growth -3.3
Gross Profit (p.s.) 17.33
Sales Per Share 24.44
EBITDA (p.s.) 8.49
Qtrly Earnings Growth -90.5
Operating Cash Flow 14,240 (M)
Levered Free Cash Flow 9,690 (M)

Stock Valuations

PE Ratio 25.92
PEG Ratio 2.1
Price to Book value 2.93
Price to Sales 3.36
Price to Cash Flow 12.23

Stock Dividends

Dividend 3.47
Forward Dividend 0
Dividend Yield 4.2%
Dividend Pay Date 2021-03-14
Ex-Dividend Date 2021-03-03
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.